Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px
Document › Details

Medigene AG. (5/28/15). "Press Release: US Patent Office Prolongs Term of Medigene's Patent Relating to Dendritic Cell (DC) Vaccines to 2031". Martinsried.

Region Region United States (USA)
Organisations Organisation Medigene AG (MDG1, Frankfurt, Prime Standard)
  Group Medigene (Group)
  Organisation 2 LMU Munich, Klinikum Großhadern
  Group LMU Munich (Ludwig-Maximilians-Universität München)
Products Product DC vaccine (dentritic cell vaccine)
  Product 2 clinical research
  Index term 2 Univ Oslo–Medigene: DC vaccine, 201504 collab existent compassionate use in academic clinical studies in solid tumours by Oslo Univ Hospital
Person Person Hofmann, Julia (Medigene 201604 PR/IR)

Biotechnology company Medigene AG (MDG1, Frankfurt, Prime Standard) announces that the US Patent Office has prolonged the term of patent no. 8,679,840 titled "Composition for the preparation of mature dendritic cells" to the year 2031. The previous term would have ended in 2028. The patent protects the process of generating mature polarised dendritic cells developed by the scientists of Medigene Immunotherapies GmbH. Dendritic cells generated with this process are being used in the ongoing clinical trials using Medigene's DC vaccines. Additionally, Medigene announced the European issue of the respective patent in March 2015. Medigene holds an exclusive licence on these patents which are central for the DC programme.

About Medigene's DC vaccines:

The platform for the development of antigen-tailored DC vaccines is the most advanced platform of the three highly innovative and complementary immunotherapy platforms of Medigene Immunotherapies.

The DC vaccines are currently being evaluated in a company-sponsored clinical trial in acute myeloid leukaemia (AML) as well as in two ongoing clinical investigator-initiated trials: a clinical phase I/II trial in AML at the Ludwig-Maximilian University Hospital Großhadern, Munich, and a clinical phase II trial in prostate cancer at the Oslo University Hospital. Moreover, a compassionate use program is being conducted at the Department of Cellular Therapy at the Oslo University Hospital.

Medigene's dendritic cell product platform allows the design of new generation dendritic cell vaccines. Dendritic cells can take up antigens efficiently, process them and present them on their surface in a form that can induce antigen-specific T cells to proliferate and mature. This way T cells can recognize and eliminate antigen-bearing tumour cells. Dendritic cells can also induce natural killer cells (NK cells) to become active and attack tumour cells. Scientists of Medigene Immunotherapies have developed new, fast and efficient methods for preparing autologous (patient-specific) mature dendritic cells which have relevant characteristics to activate both T cells and NK cells. The dendritic cells can be loaded with various tumour antigens to treat different types of cancer and are designed for treatment of minimal residual disease or use in combination therapies.

Further audio-visual education about Medigene's DCs at:

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on hematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licenced to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. Medigene ImmunotherapiesTM is a registered trademark of Medigene Immunotherapies GmbH. Trianta ImmunotherapiesTM is a registered trademark of Medigene Immunotherapies GmbH. These trademarks may be owned or licensed in select locations only.

Contact Medigene

Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01

To unsubscribe from the press release distribution list, please visit:

Record changed: 2017-04-02


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Medigene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px

» top